title: Effects of low dose total body irradiation (LDTBI) and recombinant human interleukin-2 in mice.
abstract: 10-16-Week-old female BALB/c mice received low dose total body irradiation (LDTBI) in one fraction immediately before the beginning of treatment with recombinant human interleukin-2 (rIL-2). LDTBI prevented in a dose-dependent manner the weight increase of the spleen, liver and lungs induced by fluid extravasation provoked by rIL-2 injections. It also limited the increase of the number of mononuclear cells in the spleen induced after in vivo treatment with rIL-2. Immunofluorescence analysis of spleen cells revealed that LDTBI decreased the relative sIgM+ cell number in spleen, while the relative numbers of Lyt-1+, Thy-1+ and L3T4+ cells were increased, indicating that a T and/or NK population, radioresistant to LDTBI, could still proliferate under rIL-2 stimulation in vivo. Such lymphocytes were capable of in vitro lysis of YAC cells in a 4-hour 51Cr release assay, as well as lymphokine-activated killer (LAK) cells obtained in mice treated with rIL-2 alone. Thus, LDTBI given prior to rIL-2, yet preserving the cytotoxic capacity of the LAK cells activated by rIL-2, could prevent the vascular leak syndrome toxicity induced by rIL-2 injection.
authors.affiliation: Département de Radiothérapie, INSERM U.255, Institut Curie, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Fourquet
authors.forename: J L
authors.initials: JL
authors.lastname: Teillaud
authors.forename: D
authors.initials: D
authors.lastname: Lando
authors.forename: W H
authors.initials: WH
authors.lastname: Fridman
mesh_terms: D000818:Animals; D001402:B-Lymphocytes / Q000473:pathology / Q000528:radiation effects; D002199:Capillary Permeability / Q000276:immunology* / Q000528:radiation effects*; D002452:Cell Count / Q000528:radiation effects; D003602:Cytotoxicity, Immunologic / Q000528:radiation effects; D004306:Dose-Response Relationship, Immunologic; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage / Q000494:pharmacology*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology* / Q000528:radiation effects*; D007694:Killer Cells, Natural / Q000473:pathology / Q000528:radiation effects; D008099:Liver / Q000473:pathology; D008168:Lung / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D009929:Organ Size; D011829:Radiation Dosage; D013154:Spleen / Q000276:immunology / Q000473:pathology / Q000528:radiation effects; D013601:T-Lymphocytes / Q000473:pathology / Q000528:radiation effects; D014652:Vascular Diseases / Q000517:prevention & control; D014916:Whole-Body Irradiation
chemical_list: D007376:Interleukin-2